bs-14356R

[Primary Antibody]

DNA Polymerase epsilon p59 Rabbit pAb



www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

- DATASHEET -

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GenelD: 5427 **SWISS:** P56282

Target: DNA Polymerase epsilon p59

Immunogen: KLH conjugated synthetic peptide derived from human DNA

Polymerase epsilon p59: 101-200/527.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50%

Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated

freeze/thaw cycles.

Background: DNA replication, recombination and repair, all of which are

necessary for genome stability, require the presence of

exonucleases

Applications: IHC-P (1:100-500)

IHC-F (1:100-500) **IF** (1:100-500)

Reactivity: Human, Mouse


(predicted: Rat, Sheep,

Cow, Horse)


Predicted MW.: ^{59 kDa}

Subcellular Location: Nucleus

VALIDATION IMAGES



Tissue/cell: human laryngo carcinoma; 4% Paraformaldehyde-fixed and paraffinembedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min; Incubation: Anti-POLE2 Polyclonal Antibody, Unconjugated(bs-14356R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining



Tissue/cell: Mouse embryos tissue; 4%
Paraformaldehyde-fixed and paraffinembedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min; Incubation: Anti-DNA Polymerase epsilon p59 Polyclonal Antibody, Unconjugated(bs-14356R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining

- SELECTED CITATIONS -

- [IF=11.205] Cong Lan. et al. Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction. EBIOMEDICINE. 2022 Aug;82:104139 WB;Rat. 35810562
- [IF=5.201] Zhang Chuanjie. et al. Targeting POLE2 Creates a Novel Vulnerability in Renal Cell Carcinoma via Modulating Stanniocalcin 1. Front Cell Dev Biol. 2021 Feb;9:228 IHC; Human. 33644060
- [IF=4.175] Yongjun Zhu. et al. POLE2 knockdown reduce tumorigenesis in esophageal squamous cells. Cancer Cell Int. 2020 Dec;20(1):1-12 IHC; Human. 32831648
- [IF=2.4] Sun Ming-yu. et al. POLE2 Regulates Apoptosis of Oral Squamous Cell Carcinoma Cells through the PI3K/AKT Signaling Pathway. CURR MED SCI. 2023 Dec;:1-11 IHC; Human. 38079056